Clinical Cytology in Small Animal Medicine
World Small Animal Veterinary Association World Congress Proceedings, 2004
Erik Teske, DVM, PhD, DECVIM-CA
Dept.Clin.Scie.Comp.Anim., Utrecht University
The Netherlands

An experienced cytologist examining cytological preparations can sometimes make a diagnosis in a couple of seconds. With his experience he makes use of pattern recognition. With difficult preparations, however, a more systematic approach will lead to results sooner. This is certainly true for the inexperienced cytologist. In this chapter a guideline is given for examining cytological preparations obtained by aspiration biopsy or exfoliative cytology. It is not possible in just one chapter to give a complete overview of all cytological diagnoses. Those wishing to become better qualified in cytology after reading this chapter can pursue the subject in the references that are provided.

This abstract only concerns the examination of cytological preparations. It should be realized, however, that for good diagnosis the quality of the preparation is of decisive importance. "In cytology the specimen is everything: Garbage in--Garbage out." (V. Perman, 1984). Good biopsy technique, good fixation of the smears, and good staining technique are essential. Apart from the possibility of poor quality of the biopsy, cytology has another limiting factor: a negative (e.g., tumour-negative) report is less reliable than a positive report. Severe inflammation in a tumour, necrosis of tissue in a tumour, or inadequate biopsies can result in a "false negative" report. One should always take this limitation into account. As with all diagnostic techniques it is also advisable to consider the probability of the cytological diagnosis in terms of the probability of the clinical diagnosis, and not to see it as an independent certainty. The examination of a preparation goes through three phases. The first is determining the tissue of origin, the second is differentiating among inflammation, hyperplasia/benign tumour and malignant tumour, and the third is classifying the inflammatory process or the tumour.

Tissue of origin

Because the cytological characteristics of hyperplasia, inflammation, and malignancy can differ in different tissues, it is important to first determine the most frequently occurring type of cell in the cytological preparation. The following three tissues can be distinguished.

I. Hematopoietic tissue

These are cells originating from blood, bone marrow, lymph glands, spleen, and thymus. Mast cells, histiocytes, and macrophages also belong to this category. Cells of hematopoietic origin are individual cells, mostly round in shape, and have a distinct cytoplasmic membrane. The smears are usually rich in cells. Preparations that have not been streaked out can incorrectly suggest a tissue organization, but this will be found to disappear along the edges of the smear. The cell size can vary from small to medium sized. Usually they contain little cytoplasm.

II. Epithelial glandular tissue

Cells of this type of tissue have the tendency to be connected to each other. They can form two-or three-dimensional clusters, but also monolayers or acini or duct structures. Sometimes there is a stromal component present. Individual cells can also be present. The cellularity is usually slightly less than in preparations with hematopoietic cells. Epithelial cells do also have a round nucleus. The cytoplasm is often abundant and the cell borders are distinct. Sometimes, for example in endocrine tumours, the cytoplasm is stripped from the nucleus when the smear is streaked out and there are mostly naked nuclei. The cell size can vary from small (basal cells) to very large (squamous epithelial cells).

III. Mesenchymal tissue

Within this type are included the cells arising from connective tissue, muscle, cartilage, and bone. Because of the strong attachment between the cells it is difficulty to obtain material. Smears of this type of tissue are thus also characterized by a low cellularity and the cells are mostly separate from each other, although groups of cells can also be found. The amount of cytoplasm can vary markedly and the cell borders are often rather vague. The shape of the nucleus can differ but is often oval. The cells can have characteristic morphologic forms, of which the spindle-shaped cell is the best known. Synovial cells, osteoblasts, and chondroblasts can have an egg-shaped outline in which the nucleus is eccentric and sometimes lies halfway outside the outline of the cytoplasm. Fat cells can be very large and can already be recognized at a low magnification. These cells are generally connected together as a tissue, have distinct cell margins, and have an oval nucleus that lies in the middle of the light, transparent cytoplasm.

Benign pathologic processes

Inflammation

If primarily inflammatory cells are encountered in a preparation, the process may be an acute or subacute inflammation or a more chronic and sometimes granulomatous inflammation. But it can also be a secondary inflammation in a neoplastic process. It is thus important even in the presence of inflammatory cells to continue looking for other types of cells. It is then sometimes difficult to differentiate among dysplastic, reactive, and neoplastic cells.

Inflammatory processes can be differentiated on the basis of duration (acute versus chronic), the type (purulent, pyogranulomatous, granulomatous, and eosinophilic), and the etiology (bacterial, parasitic, fungal, allergic, foreign-body reaction, etc.).

In a purulent inflammation the majority of the cells are neutrophilic polymorphonuclear leukocytes. They can account for than 85% of the cells present in an acute inflammation and decrease to 30-50% in a more chronic inflammation. In a purulent inflammation there can also be macrophages. Macrophages can be present in the inflammatory process within a couple of hours and thus they are no indication of chronicity. This is in contrast to the presence of plasma cells. These cells only arrive at the site of the inflammation after 1-2 weeks. The inflammatory process can further be characterized by the presence or absence of degenerative changes in the inflammatory cells. Karyolysis is characterized by swelling of the nucleus, less intense staining, and then disintegration of the nucleus. This is especially seen in a severe inflammation with the release of many toxic materials and proliferation of bacteria. If these characteristics are seen, a special effort must be made to look for infectious agents. In contrast, pyknosis and karyorrhexis are characteristics of a slower cell death. Pyknosis causes the nucleus to shrink markedly and to lose its chromatin pattern. The nucleus becomes a uniformly darkly stained mass. If this pyknotic nucleus disintegrates, the process is called karyorrhexis.

In a granulomatous inflammation there are fewer polymorphonuclear cells than in a purulent inflammation. In contrast, there are more macrophages and epithelioid cells. The macrophages usually show fewer signs of phagocytosis than in a purulent inflammation. There can also be multinucleated giant cells. If the infection becomes chronic, lymphocytes and plasma cells are encountered again. This type of inflammation should lead to consideration of infection by fungi, infection by actinomyces or similar bacteria, and reactions to a foreign body.

Eosinophilic inflammations contain large numbers of eosinophilic granulocytes. This type of inflammation occurs in the eosinophilic granuloma in the cat, the lick granuloma in the dog, and also in parasitic infections and allergic reactions. Eosinophilic granulocytic infiltrates are also a characteristic finding in many mast cell tumours.

Tissue regeneration

Many morphological changes related to an increased metabolic status of the cell may be present e.g., basophilic cytoplasm (high RNA-and protein content), prominent or multiple nucleoli, and increased numbers of mitoses. Differentiation with malignancy may be difficult. Usually a normal maturation of the cells can be found.

Scar tissue may be attended with young connective tissue cells and blood capillaries. Some inflammatory cells can also be found.

Neoplastic processes

For differentiation between malignant tumours and benign tumours or hyperplasia, both general criteria and cell-related (cytoplasmic and nuclear) criteria can be used. In the following paragraphs the different types of criteria of malignancy will be discussed. It must be realized that no single criterion is in itself indicative of malignancy. The nuclear criteria weigh the most heavily. In addition, the criteria are not identical for different types of cells and locations.

Table 1. Summary of cytoplasmic and nuclear characteristics of malignancy

Cytoplasmic

Nuclear

Anisocytosis

Anisokaryosis

Macrocytosis

Macrokaryosis

Basophilia

Multiple nuclei

Variable basophilia

Abnormal nuclear shapes

Abnormal cytoplasmic inclusions

Irreg. thickened nuclear membrane

Atypical vacuolization

Irreg. chromatin pattern

High N/C ratio

Hyperchromasia/anisochromasia

Variable N/C ratio

High mitotic index

Abnormal mitoses

Multiple nucleoli

Large nucleoli

Abnormally shaped nucleoli

With regard to the general criteria, the appearance of the entire population of cells is examined. The absence of inflammatory cells, the presence of a uniform cell population (i.e., one cell type) of pleomorphic cells (i.e., with variable shapes) are indications of malignancy.

A high cellularity and abnormal cellular relationships (e.g., cluster forming) can also occur with malignancy. Cluster formation means three-dimensional cell growth without organized cell relationships. In contrast, monolayers and formation of acini and ducts indicate better differentiation of the cell population. The occurrence of a type of cell where it does not usually occur makes the lesion immediately suspicious. A good example of this is the presence of epithelial cells in a lymph node.

The cytoplasmic criteria of malignancy include strong basophilia of the cytoplasm and even marked variability in basophilia of cells immediately adjacent to each other. This basophilia is related to the amount of RNA and protein synthesis in the cytoplasm and is thus a measure of the cell activity. Reactive cells can, however, also be strongly basophilic. Anisocytosis (marked variation in cell size) and macrocytosis (abnormally large cells) are more often seen in malignant than in benign tumours. Other cytoplasmic criteria of malignancy are the occurrence of abnormal cytoplasmic inclusions (especially cannibalism of other cells), atypical vacuolization, and a high nuclear/cytoplasmic (N/C) ratio (relatively little cytoplasm) and a marked variation in the N/C ratio.

The most important criteria of malignancy are, however, the nuclear criteria. Giant nuclei, anisokaryosis (difference in nuclear size), multiple nuclei per cell (especially if they also differ in size and are not 2n), abnormal nuclear shapes and marked variation in shapes, irregular and thickened nuclear membranes (especially easily seen in Papanicolaou staining), and an irregular chromatin pattern are nuclear characteristics that point to malignancy. An increased mitotic index and especially abnormal mitotic forms are other nuclear criteria of malignancy. The malignancy criteria of the nucleoli are multiple nucleoli, abnormally large nucleoli, and abnormally shaped nucleoli. Some authors have proposed that the presence of 3-4 of the above nuclear criteria of malignancy should be considered indicative of malignancy, for this number of many malignancy criteria should not occur in hyperplasia. In practice, however, it can still be difficult to differentiate between a malignant and a hyperplastic reaction, especially in mesenchymal proliferations. An overview of the most important of the above-mentioned criteria of malignancy is given in Table 1.

References

1.  Allen SW, Prasse KW. Cytologic diagnosis of neoplasia and perioperative implementation. Comp Cont Ed Pract Vet 8:72-80, 1986.

2.  Cowell RL, Tyler RD. Diagnostic Cytology of the Dog and Cat. American Veterinary Publications, Inc., Goleta, California, 1989.

3.  Lopes Cardozo P. Atlas of Clinical Cytology. Targa bv, 's Hertogenbosch, the Netherlands, 1975.

4.  Perman V, Alsaker RD, Riss RC. Cytology of the Dog and Cat. Amer Anim Hosp Assn, South Bend Indiana, 1979.

5.  Rebar AH, Handbook of Veterinary Cytology. Ralston Purina Company, St Louis, Missouri, 1979.

6.  Rebar AH. Diagnostic cytology in veterinary practice; current status and interpretative principles. In: Kirk RW (ed), Current Veterinary Therapy VII, WB Saunders Co, Philadelphia, 1980, pp 16-27.

7.  Tvedten H. Cytology of neoplastic and inflammatory masses. In: Willard, Tvedten, Turnwald (eds), WB Saunders Co, Philadelphia, 1989, pp 327-348.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Erik Teske, DVM, PhD, DECVIM-CA
Dept.Clin.Scie.Comp.Anim., Utrecht University
The Netherlands


MAIN : Clin Path : Clinical Cytology
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27